ADCETRIS 50 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion clinical trials

A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classical Hodgkin Lymphoma

This study is looking at two medicines, pembrolizumab and brentuximab vedotin, for people with Hodgkin lymphoma that has come back or hasn't responded to other treatments. It wants to see which medicine works better at stopping the cancer from growing and helping people live longer.